These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31189712)

  • 21. Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques.
    Devasundaram S; Rosati M; Valentin A; Weiss S; Itri V; Trinh HV; Bear J; Chowdhury B; LaBranche CC; Montefiori D; Ferrari G; Rao M; Kong XP; Zolla-Pazner S; Pavlakis GN; Felber BK
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33087466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.
    Rademeyer C; Korber B; Seaman MS; Giorgi EE; Thebus R; Robles A; Sheward DJ; Wagh K; Garrity J; Carey BR; Gao H; Greene KM; Tang H; Bandawe GP; Marais JC; Diphoko TE; Hraber P; Tumba N; Moore PL; Gray GE; Kublin J; McElrath MJ; Vermeulen M; Middelkoop K; Bekker LG; Hoelscher M; Maboko L; Makhema J; Robb ML; Abdool Karim S; Abdool Karim Q; Kim JH; Hahn BH; Gao F; Swanstrom R; Morris L; Montefiori DC; Williamson C
    PLoS Pathog; 2016 Jul; 12(7):e1005742. PubMed ID: 27434311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
    Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New concepts in HIV-1 vaccine development.
    Stephenson KE; D'Couto HT; Barouch DH
    Curr Opin Immunol; 2016 Aug; 41():39-46. PubMed ID: 27268856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in HIV-1 Vaccine Development.
    Gao Y; McKay PF; Mann JFS
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29614779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses.
    Fouda GG; Cunningham CK; McFarland EJ; Borkowsky W; Muresan P; Pollara J; Song LY; Liebl BE; Whitaker K; Shen X; Vandergrift NA; Overman RG; Yates NL; Moody MA; Fry C; Kim JH; Michael NL; Robb M; Pitisuttithum P; Kaewkungwal J; Nitayaphan S; Rerks-Ngarm S; Liao HX; Haynes BF; Montefiori DC; Ferrari G; Tomaras GD; Permar SR
    J Infect Dis; 2015 Feb; 211(4):508-17. PubMed ID: 25170104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.
    Gottardo R; Bailer RT; Korber BT; Gnanakaran S; Phillips J; Shen X; Tomaras GD; Turk E; Imholte G; Eckler L; Wenschuh H; Zerweck J; Greene K; Gao H; Berman PW; Francis D; Sinangil F; Lee C; Nitayaphan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Tartaglia J; Robb ML; Michael NL; Kim JH; Zolla-Pazner S; Haynes BF; Mascola JR; Self S; Gilbert P; Montefiori DC
    PLoS One; 2013; 8(9):e75665. PubMed ID: 24086607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.
    Pitisuttithum P; Nitayaphan S; Chariyalertsak S; Kaewkungwal J; Dawson P; Dhitavat J; Phonrat B; Akapirat S; Karasavvas N; Wieczorek L; Polonis V; Eller MA; Pegu P; Kim D; Schuetz A; Jongrakthaitae S; Zhou Y; Sinangil F; Phogat S; Diazgranados CA; Tartaglia J; Heger E; Smith K; Michael NL; Excler JL; Robb ML; Kim JH; O'Connell RJ; Vasan S;
    Lancet HIV; 2020 Apr; 7(4):e238-e248. PubMed ID: 32035516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV Vaccination: A Roadmap among Advancements and Concerns.
    Trovato M; D'Apice L; Prisco A; De Berardinis P
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29671786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
    Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional implications of the binding mode of a human conformation-dependent V2 monoclonal antibody against HIV.
    Spurrier B; Sampson J; Gorny MK; Zolla-Pazner S; Kong XP
    J Virol; 2014 Apr; 88(8):4100-12. PubMed ID: 24478429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is developing an HIV-1 vaccine possible?
    Haynes BF; Liao HX; Tomaras GD
    Curr Opin HIV AIDS; 2010 Sep; 5(5):362-7. PubMed ID: 20978375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity.
    Mayr LM; Decoville T; Schmidt S; Laumond G; Klingler J; Ducloy C; Bahram S; Zolla-Pazner S; Moog C
    Sci Rep; 2017 Oct; 7(1):12655. PubMed ID: 28978939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategies for eliciting HIV-1 inhibitory antibodies.
    Tomaras GD; Haynes BF
    Curr Opin HIV AIDS; 2010 Sep; 5(5):421-7. PubMed ID: 20978384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.
    Easterhoff D; Moody MA; Fera D; Cheng H; Ackerman M; Wiehe K; Saunders KO; Pollara J; Vandergrift N; Parks R; Kim J; Michael NL; O'Connell RJ; Excler JL; Robb ML; Vasan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Nitayaphan S; Sinangil F; Tartaglia J; Phogat S; Kepler TB; Alam SM; Liao HX; Ferrari G; Seaman MS; Montefiori DC; Tomaras GD; Harrison SC; Haynes BF
    PLoS Pathog; 2017 Feb; 13(2):e1006182. PubMed ID: 28235027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development.
    Rao M; Peachman KK; Kim J; Gao G; Alving CR; Michael NL; Rao VB
    Curr HIV Res; 2013 Jul; 11(5):427-38. PubMed ID: 24191938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.
    Yates NL; Liao HX; Fong Y; deCamp A; Vandergrift NA; Williams WT; Alam SM; Ferrari G; Yang ZY; Seaton KE; Berman PW; Alpert MD; Evans DT; O'Connell RJ; Francis D; Sinangil F; Lee C; Nitayaphan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Tartaglia J; Pinter A; Zolla-Pazner S; Gilbert PB; Nabel GJ; Michael NL; Kim JH; Montefiori DC; Haynes BF; Tomaras GD
    Sci Transl Med; 2014 Mar; 6(228):228ra39. PubMed ID: 24648342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials.
    Zolla-Pazner S; Michael NL; Kim JH
    Lancet HIV; 2021 Jul; 8(7):e449-e452. PubMed ID: 34029515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.
    Rolland M; Edlefsen PT; Larsen BB; Tovanabutra S; Sanders-Buell E; Hertz T; deCamp AC; Carrico C; Menis S; Magaret CA; Ahmed H; Juraska M; Chen L; Konopa P; Nariya S; Stoddard JN; Wong K; Zhao H; Deng W; Maust BS; Bose M; Howell S; Bates A; Lazzaro M; O'Sullivan A; Lei E; Bradfield A; Ibitamuno G; Assawadarachai V; O'Connell RJ; deSouza MS; Nitayaphan S; Rerks-Ngarm S; Robb ML; McLellan JS; Georgiev I; Kwong PD; Carlson JM; Michael NL; Schief WR; Gilbert PB; Mullins JI; Kim JH
    Nature; 2012 Oct; 490(7420):417-20. PubMed ID: 22960785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV.
    Zolla-Pazner S; Alvarez R; Kong XP; Weiss S
    Curr Opin HIV AIDS; 2019 Jul; 14(4):309-317. PubMed ID: 30994501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.